“Lebrikizumab Monotherapy Reduces Flares in Patients with Moderate-to-Severe Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s147. doi:10.25251/skin.7.supp.147.